Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,812 total articles

Micron: Why the 'Peak Memory' Narrative Is Overstated — a Tactical Long

Micron: Why the 'Peak Memory' Narrative Is Overstated — a Tactical Long

Short-term headlines about memory efficiency (TurboQuant) have pressured Micron shares, but the company’s cash flow, tight HBM/SRAM supply for AI accelerators, and a still-reasonable valuation argue for a tactical long. This trade plan targets a move back toward the 52-week highs as markets reprice durable demand, with a clear stop to limit downsid…

Netflix Q1 Preview - Buying the Dip Ahead of the April 16 Print

Netflix Q1 Preview - Buying the Dip Ahead of the April 16 Print

Netflix's recent price increases, accelerating ad revenue, and a cleaner balance sheet after walking away from a large M&A bid create a high-probability asymmetric trade into the April 16 earnings report. Valuation is busy but not extreme for a company with $9.46B in free cash flow and an EV/EBITDA of 10.8. Entry at $97.66, stop $85, target $130 ov…

Buy EWY on an Iran Ceasefire: Korea's AI-Led Rally Has More Room to Run

Buy EWY on an Iran Ceasefire: Korea's AI-Led Rally Has More Room to Run

The iShares MSCI South Korea ETF (EWY) is a leveraged way to own Korea's AI-driven memory cycle and corporate reform story. If the Iran war ends and energy-driven risk premia roll off, EWY should re-rate from cyclical discount to growth multiple. We lay out an actionable long trade with entry, stop, targets and a balanced view of catalysts and risk…

JBSS: Buy the Family Nut Processor Set for a Re-rating

JBSS: Buy the Family Nut Processor Set for a Re-rating

John B. Sanfilippo & Son (JBSS) is a family-run nut processor trading below $1.0 billion market cap, generating solid free cash flow and mid-teens returns on equity. With EPS up sharply in the latest fiscal quarter, conservative balance sheet metrics, and a share base under 12 million, JBSS is a candidate for a measured long trade to capture a mult…

Booking After the 25-for-1 Split: A Tactical Long With Measured Upside

Booking After the 25-for-1 Split: A Tactical Long With Measured Upside

Booking Holdings completed a 25-for-1 forward split on 04/02/2026 that should amplify retail demand and liquidity. Fundamentals remain solid — high free cash flow, mid-20s P/E, and 2025 revenue and EPS growth — making a disciplined long the preferred trade over the next 45 trading days. Risk is real: macro travel shocks, TSA disruptions, and moment…

Buying Orla Mining After the Pullback: A Growth-Weighted Gold Bet

Buying Orla Mining After the Pullback: A Growth-Weighted Gold Bet

Orla Mining has pulled back from recent highs but fundamentals and the macro gold picture argue for a constructive stance. Recent quarterly beats, steady production, a newly instituted quarterly dividend, and exploration upside make ORLA a compelling long trade over the next 180 trading days. I lay out an entry, stop, targets, catalysts and balance…

CoreWeave Revisited: Why I'm Reiterating a Buy on CRWV

CoreWeave Revisited: Why I'm Reiterating a Buy on CRWV

<p>CoreWeave remains my preferred pure-play bet on GPU infrastructure despite clear execution and balance-sheet risks. The company sits on a multiyear demand wave from generative AI, a massive contracted backlog, and accelerating revenue guidance. That combination justifies a high-risk, high-reward long position with disciplined sizing.</p>

Microsoft's AI Reset: A Tactical Long After the Sell-Off

Microsoft's AI Reset: A Tactical Long After the Sell-Off

Microsoft's shares have been punished as investors price in a multi-year AI infrastructure build and near-term margin pressure. At $369.91, the stock trades at a materially lower multiple than its 2025 peak and offers cash-flow durability, a fortress balance sheet and exposure to cloud/AI secular growth. This trade idea lays out a mid-term (45 trad…

Buy MKKGY: Diversified Pharma & Life-Science Exposure at a Value Entry

Buy MKKGY: Diversified Pharma & Life-Science Exposure at a Value Entry

Merck KGaA (MKKGY) combines a high-quality life-science tools franchise, steady pharma royalties and specialty materials. At $25.44 the stock trades at a reasonable P/E of 18.3 and a market cap of roughly $55.3B, offering a compelling risk/reward for a long trade targeting the $31 52-week high. Technicals show constructive momentum (EMA cross, MACD…